Century Therapeutics Faces Delisting Notice
Ticker: IPSC · Form: 8-K · Filed: Aug 29, 2025 · CIK: 1850119
Sentiment: bearish
Topics: delisting, listing-standards, regulatory
TL;DR
Century Therapeutics got a notice about possibly getting delisted.
AI Summary
Century Therapeutics, Inc. filed an 8-K on August 29, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard as of August 27, 2025. The company is incorporated in Delaware and its principal executive offices are located in Philadelphia, Pennsylvania.
Why It Matters
This filing indicates potential issues with Century Therapeutics' compliance with stock exchange listing requirements, which could lead to the stock being delisted.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's stock trading and investor confidence.
Key Players & Entities
- Century Therapeutics, Inc. (company) — Registrant
- August 27, 2025 (date) — Earliest event reported
- August 29, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- Philadelphia, Pennsylvania (location) — Principal executive offices
- 267-817-5790 (phone_number) — Registrant's telephone number
FAQ
What specific listing rule or standard has Century Therapeutics failed to satisfy?
The filing does not specify the exact rule or standard that Century Therapeutics has failed to satisfy, only that a notice has been issued.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is August 27, 2025.
When was this 8-K form filed with the SEC?
This 8-K form was filed on August 29, 2025.
Where are Century Therapeutics' principal executive offices located?
Century Therapeutics' principal executive offices are located at 25 North 38th Street, 11th Floor, Philadelphia, Pennsylvania, 19104.
What is the company's state of incorporation?
The company's state of incorporation is Delaware.
Filing Stats: 819 words · 3 min read · ~3 pages · Grade level 12.6 · Accepted 2025-08-29 16:10:51
Key Financial Figures
- $0.0001 — ch Registered Common Stock, par value $0.0001 per share IPSC Nasdaq Capital Marke
- $1.00 m — Company was not in compliance with the $1.00 minimum bid price requirement for continu
- $1.00 — the Company's common stock is at least $1.00 per share for a minimum of 10 consecuti
Filing Documents
- tm2524509d1_8k.htm (8-K) — 27KB
- 0001104659-25-085658.txt ( ) — 190KB
- ipsc-20250827.xsd (EX-101.SCH) — 3KB
- ipsc-20250827_lab.xml (EX-101.LAB) — 33KB
- ipsc-20250827_pre.xml (EX-101.PRE) — 22KB
- tm2524509d1_8k_htm.xml (XML) — 4KB
01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On February 26, 2025, Century Therapeutics, Inc. (the " Company ") received a deficiency letter from the Nasdaq Listing Qualifications Staff (" Staff ") of The Nasdaq Stock Market LLC (" Nasdaq ") notifying the Company that based on the closing bid price for the last 30 consecutive business days, the Company was not in compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Global Select Market, as set forth in Nasdaq Listing Rule 5450(a)(1) (the " Bid Price Rule "). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided a period of 180 calendar days, or until August 26, 2025 (the " Initial Compliance Date "), to regain compliance with the Bid Price Rule. The Company did not regain compliance with the Bid Price Rule by the Initial Compliance Date. On August 27, 2025, Nasdaq notified the Company that it had granted the Company an additional 180 calendar day period, or until February 23, 2026 (the " Extended Compliance Date "), to regain compliance with the Bid Price Rule. Nasdaq's determination was based on, among other things, (1) the Company meeting the continued listing requirement for market value of publicly held shares and all other initial listing requirements for The Nasdaq Capital Market, with the exception of the Bid Price Rule, and (2) the Company's written notice of its intention to cure the deficiency by effecting a reverse stock split, if necessary. On August 27, 2025, Nasdaq approved the Company's transfer from The Nasdaq Global Select Market to The Nasdaq Capital Market. This transfer became effective at the opening of business on August 27, 202 and the Company's common stock continues to trade under the symbol "IPSC." The Nasdaq Capital Market is a continuous trading market that operates in substantially the same manner as The Nasdaq Global Select Market, and listed companies mus
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CENTURY THERAPEUTICS, INC. By: /s/ Brent Pfeiffenberger, Pharm.D. Name: Brent Pfeiffenberger, Pharm.D. Title: President and Chief Executive Officer Date: August 29, 2025